en POLSKI
eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank


Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
1/2007
vol. 45
 
Share:
Send email
Share:
abstract:

Original paper
Leflunomide in treatment of rheumatoid arthritis patients

Maria Rell-Bakalarska
,
Lidia Rutkowska-Sak
,
Małgorzata Kwiatkowska
,
Barbara Lisowska
,
Elżbieta Wojtecka-Łukasik
,
Sławomir Maśliński

Reumatologia 2007; 45, 1: 6–10
Online publish date: 2007/03/12
View full text Get citation
 
The aim of this study was to investigate the effectiveness and safety of leflunomide in the treatment of rheumatoid arthritis (RA). Therapy with leflunomide was performed on 276 patients with active RA, defined by a disease activity score (DAS). All patients had previously been given conventional drug treatment without positive effects. The mean duration of leflunomide treatment was 16 months. Adverse events related to leflunomide therapy were evaluated. Before and after treatment, the serum activity of cartilage enzymes (NAH-ase and NTPPH-ase) was normal. The efficacy of leflunomide was shown in 70% of cases. This therapy proved ineffective in approximately 13% of patients. The results of this study demonstrated that leflunomide treatment had to be discontinued in 18% of patients because of adverse effects.
keywords:

rheumatoid arthritis, leflunomide, effectiveness and safety, cartilage enzymes
EVENTS/KONFERENCJE
BOOKS/KSIĄŻKI



Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.